| Income statement (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | 29.44B | 28.75B | 27.12B | 27.28B | 27.30B | 24.69B |
| Cost of revenue | 6.23B | 6.25B | 6.50B | 5.66B | 6.60B | 4.57B |
| Gross profit | 23.21B | 22.50B | 20.62B | 21.62B | 20.70B | 20.12B |
| Research and development | 5.80B | 5.91B | 5.72B | 4.98B | 4.60B | 4.93B |
| Selling, general and admin | 5.77B | 6.09B | 6.09B | 5.67B | 5.25B | 5.15B |
| Operating expenses | 19.42B | 27.09B | 19.51B | 19.95B | 17.39B | 20.62B |
| Operating income | 10.02B | 1.66B | 7.61B | 7.33B | 9.92B | 4.07B |
| EBITDA | 10.39B | 2.04B | 7.96B | 7.65B | 10.25B | 4.36B |
| Interest expense | 1.02B | 977.00M | 944.00M | 935.00M | 1.00B | 984.00M |
| Income before tax | 9.80B | 690.00M | 6.86B | 5.81B | 8.28B | 1.67B |
| Income tax | 1.29B | 211.00M | 1.25B | 1.25B | 2.08B | 1.58B |
| Net income | 8.51B | 480.00M | 5.67B | 4.59B | 6.22B | 123.00M |
| EPS | 6.84 | 0.38 | 4.54 | 3.66 | 4.96 | 0.10 |
| EPS (diluted) | 6.78 | 0.38 | 4.50 | 3.64 | 4.93 | 0.10 |
| Diluted shares | 1.25B | 1.25B | 1.26B | 1.26B | 1.26B | 1.26B |
| Dividends per share | 3.16 | 3.08 | 3.00 | 2.92 | 2.84 | 2.72 |
From Gilead Sciences's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.